Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Best Pract Res Clin Haematol. 2013 Sep;26(3):245-8. doi: 10.1016/j.beha.2013.10.003. Epub 2013 Oct 15.
Specific combinations of mutations, including FLT3 and IDH1/IDH2/TET2, frequently co-occur in acute myeloid leukemia (AML) and are associated with poor prognosis. These mutation combinations can be modeled in mice to provide a more genetically accurate model of AML. Within these models, stem cells may be different depending on how experiments are conducted and based on context. No one mutation can turn on a gene; rather the perfect storm of the right genes in the right cell is necessary to produce AML. Furthermore, this understanding is therapeutically relevant. Rapid and accurate targeted DNA sequencing will identify mutations of prognostic and therapeutic significance and will guide treatment choices in the future.
特定的突变组合，包括 FLT3 和 IDH1/IDH2/TET2，在急性髓系白血病（AML）中经常同时发生，并与不良预后相关。这些突变组合可以在小鼠中建模，为 AML 提供更具遗传准确性的模型。在这些模型中，干细胞可能会因实验方式和背景的不同而有所不同。单一突变并不能激活一个基因；而是需要在正确的细胞中出现正确的一组基因，才能产生 AML。此外，这种理解在治疗上具有相关性。快速而准确的靶向 DNA 测序将鉴定出具有预后和治疗意义的突变，并将指导未来的治疗选择。
